June 10, 2009

Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients.


Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177
.   .   

Previous comparisons of IL-2 receptor antibodies and thymoglobulin compared either low-risk patients, or patients at high risk due to long cold ischemia times. This trial enrolled patients at high immunologic risk (mean peak PRA around 70%). Thymoglobulin reduced the risk of biopsy-proven acute rejection, but this trial was not powered to look at differences in graft or patient survival.

Renal Transplantation